



An insect-tapeworm model as a proxy for anthelmintic effects in the mammalian host

Woolsey, Ian David; Fredensborg, Brian Lund; Jensen, Per Moestrup; Kapel, Christian Moliin Outzen; Meyling, Nicolai Vitt

Published in:
Parasitology Research

DOI:
[10.1007/s00436-015-4477-0](https://doi.org/10.1007/s00436-015-4477-0)

Publication date:
2015

Document version
Peer reviewed version

Citation for published version (APA):
Woolsey, I. D., Fredensborg, B. L., Jensen, P. M., Kapel, C. M. O., & Meyling, N. V. (2015). An insect-tapeworm model as a proxy for anthelmintic effects in the mammalian host. *Parasitology Research*, 114(7), 2777-2780. <https://doi.org/10.1007/s00436-015-4477-0>

Parasitology Research

An insect-tapeworm model as a proxy for anthelmintic effects in the mammalian host.

--Manuscript Draft--

Manuscript Number:	PARE-D-15-00225R1
Full Title:	An insect-tapeworm model as a proxy for anthelmintic effects in the mammalian host.
Article Type:	Short Communication
Funding Information:	
Abstract:	<p>Invertebrate models provide several important advantages over their vertebrate counterparts including fewer legislative stipulations and faster, more cost-effective experimental procedures. Furthermore, various similarities between insect and mammalian systems have been highlighted. To obtain maximum use of invertebrate models in pharmacology, their fidelity as analogues of vertebrate systems requires verification. We utilised a flour beetle (<i>Tenebrio molitor</i>) - tapeworm (<i>Hymenolepis diminuta</i>) model to evaluate the efficacy of known anthelmintic compounds, praziquantel, mebendazole and levamisole against <i>H. diminuta</i> cysticercoid larvae in vitro. Inhibition of cysticercoid activity during the excystation procedure was used as a proxy for worm removal. The effects of the three compounds mirrored their relative efficacy in treatment against adult worms in mammalian systems; however, further study is required to determine the fidelity of this model in relation to dose administered. The model precludes comparison of consecutive daily administration of pharmaceuticals in mammals due to cysticercoids not surviving outside of the host for multiple days. Treatment of beetles in vivo, followed by excystation of cysticercoids post dissection could potentially allow for such comparisons. Further model validation will include analysis of pharmaceutical efficacy in varying <i>H. diminuta</i> isolates and pharmaceutical dilution in solvents other than water. Notwithstanding, our results demonstrate that this model holds promise as a method to efficiently identify promising new cestocidal candidates.</p>
Corresponding Author:	Ian David Woolsey, MSc DENMARK
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	
Corresponding Author's Secondary Institution:	
First Author:	Ian David Woolsey, MSc
First Author Secondary Information:	
Order of Authors:	Ian David Woolsey, MSc Brian L Fredensborg, Ph.D Per M Jensen, Ph.D Christian M. O. Kapel, Ph.D Nicolai V Meyling, Ph.D
Order of Authors Secondary Information:	
Author Comments:	

Dear Editor,

More details have now been added to the abstract. I have incorporated some of reviewer #1 comments into the discussion and have checked that all species and genus names are italicised.

The old name of the journal in the references has now been amended to Parasitol Res.

Regards,

Ian Woolsey.

1 **An insect-tapeworm model as a proxy for anthelmintic effects in the**
2 **mammalian host.**

3
4
5
6
7 4 Ian David Woolsey, Brian L. Fredensborg, Per M. Jensen, Christian M.O. Kapel,
8
9 5 Nicolai V. Meyling

10
11
12 6
13
14 7 Department of Plant and Environmental Sciences, University of Copenhagen,
15
16 8 Thorvaldsensvej 40, 1871 Frederiksberg C.

17
18
19 9
20
21 10 **Word count:**

22
23
24 11 Abstract: 213

25
26 12 Article: 1587

27
28
29 13
30
31 14 Corresponding author: Ian Woolsey, e-mail: ianwoolsey@plen.ku.dk,

32
33
34 15 Phone: +45 26 70 60 96.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

16 **Abstract**

17 Invertebrate models provide several important advantages over their vertebrate counterparts including
18 fewer legislative stipulations and faster, more cost-effective experimental procedures. Furthermore,
19 various similarities between insect and mammalian systems have been highlighted. To obtain
20 maximum use of invertebrate models in pharmacology, their fidelity as analogues of vertebrate systems
21 requires verification. We utilised a flour beetle (*Tenebrio molitor*) – tapeworm (*Hymenolepis diminuta*)
22 model to evaluate the efficacy of known anthelmintic compounds, praziquantel, mebendazole and
23 levamisole against *H. diminuta* cysticercoid larvae *in vitro*. Inhibition of cysticercoid activity during
24 the excystation procedure was used as a proxy for worm removal. The effects of the three compounds
25 mirrored their relative efficacy in treatment against adult worms in mammalian systems; however,
26 further study is required to determine the fidelity of this model in relation to dose administered. The
27 model precludes comparison of consecutive daily administration of pharmaceuticals in mammals due
28 to cysticercoids not surviving outside of the host for multiple days. Treatment of beetles *in vivo*,
29 followed by excystation of cysticercoids post dissection could potentially allow for such comparisons.
30 Further model validation will include analysis of pharmaceutical efficacy in varying *H. diminuta*
31 isolates and pharmaceutical dilution in solvents other than water. Notwithstanding, our results
32 demonstrate that this model holds promise as a method to efficiently identify promising new cestocidal
33 candidates.

35 **Key words**

36 Cestode, anthelminthic, *Hymenolepis diminuta*, host-parasite model, *Tenebrio molitor*

38 **Introduction**

39 Mammal testing remains the gold standard to screen potential drug compounds for various
40 toxicological and pharmacological effects in humans (Baumans 2004). The general public and the
41 scientific community have however increasingly opposed the use of experimental animals and sought
42 to Reduce, Refine and Replace (the 3R's) vertebrate experimentation (Schuppli et al. 2004). The use of
43 invertebrate models would constitute one method of Reduction or potentially Replacement (nc3rs
44 2014). The invertebrate innate immune response to infection resembles that in humans (Hoffmann et al.
45 1999; Kavanagh and Reeves 2007; Kimbrell and Beutler 2001), and insects have been used as

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46 immunological research models (Pursall and Rolff 2011). As invertebrates are presently not subject to
47 experimental animal legislation that applies to vertebrates, less administrative efforts are required to
48 ensure appropriate standards of welfare (Kemp and Massey 2007). Furthermore, in many invertebrate
49 species, particularly insects, experimental processes are often quicker and their high rate of
50 reproduction means they can be produced in large quantities in a relatively short time resulting in faster
51 dissemination of results (Scully and Bidochka 2006). Finally, laboratory space required is minimal due
52 to much smaller housing stipulations involved in using insects (Steinert et al. 2003).

53
54 The cosmopolitan rat tapeworm *Hymenolepis diminuta* Rudolphi, 1819 has been used as an
55 experimental model for decades. Whilst it very rarely infects humans and is easily treatable (Tanowitz
56 et al. 2001), it is often used as a teaching model for two reasons: i) the ease of maintenance of both
57 stages of the parasitic life cycle (cysticercoid larvae in flour beetles and adult worm in rats), and ii) the
58 helminth represents the same basic sequence of development as most other cestodes. Thus, the study of
59 *H. diminuta* has made substantial contributions to our understanding of cestodes in general including
60 their survival, reproduction and development strategies (Mansur et al. 2014). The use of an invertebrate
61 intermediate host of this parasite enables the possibility of anthelmintic screening with limited use of
62 vertebrates. Indeed, cysticercoids of *H. diminuta* isolated from infected beetles have been used to
63 deduce mechanisms of cestocidal activity of plant derived cysteine proteinases (found in papaya and
64 pineapple etc.) (Mansur et al. 2014) and condensed tannins (Dhakai et al. 2015). In addition, Novak
65 and Evans (1978) demonstrated that mebendazole can retard development of *H. diminuta* cysticercoids
66 when fed to *Tribolium confusum* du Val, 1863 beetles suggesting a similar mode of action of the drug
67 towards the cysticercoid stage inside insects to the adult worm inside the mammalian host.

68
69 If the pharmacologic and toxicological parameters of potential cestocidal compounds, including plant
70 extracts, can be achieved using an insect – tapeworm model it could significantly increase the speed at
71 which such compounds are available as alternatives to current anthelmintics as well as reducing the
72 amount of vertebrates necessary for experiments.

73
74 In this study, we assessed the usefulness of the *Tenebrio molitor* (Linnaeus, 1758) -*H. diminuta* model
75 as a proxy for the mammalian system by evaluating: 1) if the effects of the three commonly used

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

76 anthelmintics, praziquantel, mebendazole, and levamisole on cysticercoids of *H. diminuta* resemble the
77 effects known from adult worms in the rat host (qualitative similarity), and 2) if varying concentrations
78 of the pharmaceutical alter the inhibition of larval cestodes from insects as they do in mammalian
79 systems (quantitative similarity). We assessed anticestodal effects as the rate of inhibition of *in vitro*
80 excystation of cysticercoids when exposed to the physico-chemical conditions mimicking the digestive
81 processes in the gastrointestinal tract of the rat.

82
83 Praziquantel is a highly effective drug against adult cestodes in mammals (McKellar and Jackson 2004;
84 Thomas and Grönnert 1977), and we therefore hypothesized a strong inhibitory effect of praziquantel
85 on cysticercoid excystation. In contrast, mebendazole shows a moderate effect on adult cestodes
86 (McCracken, Lipkowitz et al. 1992), but it is widely used to treat nematode infections in humans
87 (Bennett and Guyatt 2000). Inhibitory effects of mebendazole on cysticercoid excystation are therefore
88 only expected at relatively high concentrations. Levamisole is a nematicidal drug showing no effect on
89 adult cestodes in mammals (Bennett, Behm et al. 1978), and it therefore served as a negative control in
90 this study.

91

92 **Materials and methods**

93 *Pharmaceutical formulation and application*

94 Stock solutions of praziquantel (Droncit[®]), mebendazole (Vermox[®]) and levamisole hydrochloride
95 were mixed with Mill-Q[®] water in order to create the desired concentrations of 0.05, 0.005, 0.0005 and
96 0.00005%.

97

98 Infected *T. molitor* beetles (infection protocol as in Dhakal et al. 2015) were dissected with 0.9%
99 physiological saline in a petri dish. Cysticercoid cysts were counted then removed with a Pasture
100 Pipette and placed in watch glasses (33 mm diameter, 7 mm deep). Ten cysts were placed in each of 15
101 watch glasses containing either one of the 3 drugs at the 4 different concentrations or saline control.
102 Three controls were prepared, one for each drug. No more than 4 cysticercoids from a single beetle
103 were used per watch glass. Once all cysts had been positioned, saline was removed from the glass with
104 a pipette and 0.5ml of the desired anthelmintic or saline was applied. Watch glasses were then placed
105 on a Centromat[®] rotating table for 60 minutes at 50 rpm at room temperature. The experiment was

106 repeated at three separate occasions, and these repeats were pooled for final analysis leading to 30
107 observations for each pharmaceutical at each concentration.

108

109 *Excystation*

110 Cysticercoid excystation was achieved utilizing a modified existing protocol (Goodchild and Davis
111 1972). Briefly, anthelmintic was removed with a Pasteur Pipette and 2 ml HCl-Pepsin solution [2 ml 37
112 % HCl, 20 ml 37°C 0.9 % saline, 0.8 g pepsin powder from porcine gastric mucosa (1:2500, Sigma
113 Life Science)] was added to each watch glass and placed in an incubator at 37°C for 10 minutes. The
114 HCl-Pepsin solution was then removed by pipette and the cysticercoids were washed 3 times with
115 saline (approx. 2 ml), to remove any remaining acid, after which 1 ml of trypsin-taurocholate solution
116 [0.1 g sodium taurocholate hydrate powder, 0.1 g trypsin powder from porcine pancreas, (97 %, Sigma
117 Life Science), 10 ml warm phosphate-buffered saline (PBS) was added. The cysticercoids were then
118 placed in the incubator at 37°C for 180 minutes.

119

120 *Cysticercoid observations*

121 Cysticercoids were graded on a 2-point scale; 0 – no visible sign of activity; or 1 – movement within
122 the cysticercoid or full excystation, that is, protrusion of the scolex from the cysticercoid capsule. To
123 differentiate between type 0 and 1, each cysticercoid was observed at 100 × magnification for 10
124 seconds.

125

126 *Statistical analysis*

127 Paired comparisons, across all pharmaceuticals and concentrations (including their respective controls),
128 were executed under a generalised (binomial) linear model, which provided information on statistical
129 differences for each comparison (total pairs = 35, each having 30 observations). The analyses were
130 conducted under PROC GENMOD in SAS 9.1 for Windows (SAS Institute, Cary NC, USA), which
131 also provided information on the effect of concentrations for each pharmaceutical.

132

133 **Results and Discussion**

134 Across all concentrations, praziquantel was significantly more inhibitory than mebendazole (0.05%
135 $p=0.0128$, 0.005% $p=0.0128$, 0.0005% $p=0.0168$ and 0.00005% $p=0.0012$) and levamisole (0.05%

136 $p=0.0002$, 0.005% $p=0.0001$, 0.0005% $p=0.0002$, 0.00005% $p=0.0001$). Mebendazole was only
137 significantly more inhibitory against levamisole at the highest two concentrations (0.05% $p=0.0114$,
138 0.005% $p=0.0026$, 0.0005% $p=0.0960$ and 0.00005% $p=0.2274$). The inhibitory effect on excystation
139 was dose-dependent both for praziquantel ($p=0.0001$) and mebendazole ($p=0.0001$) but not for
140 levamisole where no significant reduction in excystation was observed ($p=0.0633$) (Fig. 1).
141
142 Thus, the greatest inhibitory effect of anthelmintic on cysticeroid activity was observed for
143 praziquantel, followed by mebendazole whereas no significant inhibition could be demonstrated for
144 levamisole. This trend was observed across all concentrations and indeed, qualitatively the drugs
145 appear to be mirroring their comparative levels of efficacy in the mammalian system against adult
146 cestodes (Bennett et al. 1978; Dayan 2003; McCracken et al. 1992; Thomas and Grönnert 1977).
147 Furthermore, differing concentrations of the drugs *in vitro* have a significant affect on cysticeroid
148 inhibition. This corresponds to mammalian models in which differing doses of pharmaceuticals
149 administered result in varying worm expulsion efficacy. In rats, 100% reduction in *H. diminuta* worm
150 burden has been demonstrated with 5 mg/kg praziquantel application, while 0.5 mg/kg resulted in a
151 53% worm burden reduction (Thomas and Gönnert 1977). In this study both praziquantel and
152 mebendazole were observed to be significantly less inhibitory at lower concentrations. Due to this
153 varying cysticeroid inhibition as a function of concentration, future studies could focus on calibrating
154 concentrations *in vitro* with worm expulsion in mammals in an effort to enhance quantitative similarity
155 of this model. Furthermore, the variability (or lack thereof) in pharmaceutical efficacy in different *H.*
156 *diminuta* isolates should be considered as well as pharmaceutical dilutions in solvents other than water.
157
158 When utilizing mebendazole against cestode infections a number of studies employ consecutive daily
159 treatment of the drug (Maki and Yanagisawa 1985; McCracken et al. 1992; Varma et al. 1989). As
160 cysticeroids will not survive outside of the host for multiple days, comparisons of such studies with
161 this model are precluded. Treatment of beetles *in vivo*, followed by excystation of cysticeroids post
162 dissection could potentially allow for such comparisons.
163
164 Although the quantitative properties in relation to concentration administered need further exploration
165 in the present model, our study demonstrates that the relative effects of the three anthelmintics in

166 mammalian systems were mirrored by the cysticercoid excystation assay. Therefore, this model has the
167 potential to function as a rapid and cost-effective screening technique of anthelmintic candidates for
168 further testing. Additionally, the *T. molitor* - *H. diminuta* model may significantly reduce the number of
169 vertebrates needed for initial drug screening complying with the increasing demand for a reduction in
170 the number of vertebrates used in biomedical research.

171

172

173 **Funding:** This research was supported by a starting grant from the programme “Synergy in Human and
174 Animal Research (SHARE)” at the University of Copenhagen and a research grant (no. 00007457)
175 from the Villum Foundation.

176

177 **Conflict of interest:** The authors declare that they have no conflict of interest.

178

179 **Ethical approval:** All applicable international, national, and/or institutional guidelines for the care and
180 use of animals were followed. All procedures performed in studies involving animals were in
181 accordance with the ethical standards of the institution or practice at which the studies were conducted
182 (Danish Experimental Animal Inspectorate permission no. 2010/561-1914 –section C10).

183

184 **References**

- 185 Baumans V (2004) Use of animals in experimental research: an ethical dilemma? *Gene Ther* 11 Suppl
186 1:S64-66
- 187 Bennett A, Guyatt H (2000) Reducing Intestinal Nematode Infection: Efficacy of Albendazole and
188 Mebendazole. *Parasitol Today* 16:71-74
- 189 Bennett HM, Behm C, Bryant C (1978) Effects of mebendazole and levamisole on tetrathyridia of
190 *Mesocostoides corti* in the mouse. *Int J Parasitol* 8:463-466
- 191 Dayan AD (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and
192 pharmacokinetics *Acta Trop.* 86:141-159
- 193 Dhakal S, Meyling NV, Williams AR, Mueller-Harvey I, Fryganas C, Kapel CM, Fredensborg BL (2015)
194 Efficacy of condensed tannins against larval *Hymenolepis diminuta* (Cestoda) in vitro and in
195 the intermediate host *Tenebrio molitor* (Coleoptera) in vivo. *Vet Parasitol* 207:49-55
- 196 Goodchild CG, Davis BO (1972) *Hymenolepis microstoma* Cysticercoid Activation and Excystation In
197 vitro (Cestoda) *J. Parasitol.* 58:735-741
- 198 Hoffmann JA, Kafatos FC, Janeway CA, Ezekoitz RAB (1999) Phylogenetic Perspectives in Innate
199 Immunity. *Science* 284:1318
- 200 Kavanagh K, Reeves EP (2007) Insect and mammalian innate immune responses are much alike.
201 *Microbe* 2:596-599
- 202 Kemp MW, Massey RC (2007) The use of insect models to study human pathogens. *Drug Discov*
203 *Today: Dis Models* 4:105-110
- 204 Kimbrell DA, Beutler B (2001) The evolution and genetics of innate immunity. *Nature* 2:256-267

1 205 Maki J, Yanagisawa T (1985) Anthelmintic effects of bithionol, paromomycin sulphate, flubendazole
2 206 and mebendazole on mature and immature *Hymenolepis nana* in mice J. Helminthol 59:211-
3 207 216
4 208 Mansur F, Luoga W, Buttle DJ, Duce IR, Lowe A, Behnke JM (2014) The anthelmintic efficacy of natural
5 209 plant cysteine proteinases against two rodent cestodes *Hymenolepis diminuta* and
6 210 *Hymenolepis microstoma* in vitro. Vet Parasitol 201:48-58
7 211 McCracken RO, Lipkowitz KB, Dronen NO (1992) Efficacy of albendazole and mebendazole against
8 212 *Hymenolepis microstoma* and *Hymenolepis diminuta*. Parasitol Res 78:108-111
9 213 McKellar QA, Jackson F (2004) Veterinary anthelmintics: old and new trends. Parasitol
10 214 20:456-461
11 215 nc3rs (2014) What are the 3Rs? <http://www.nc3rs.org.uk/the-3rs>. Accessed 11/11/2014 2014
12 216 Novak M, Evans W (1978) The effect of mebendazole on different developmental stages of
13 217 *Hymenolepis diminuta* cysticercoids. Can. J. Zool 56:604-607
14 218 Pursall ER, Rolff J (2011) Immune Responses Accelerate Ageing: Proof-of-Principle in an Insect
15 219 Model. PLoS One 6:1-7
16 220 Schuppli CA, Fraser D, McDonald M (2004) Expanding the three Rs to meet new challenges in humane
17 221 animal experimentation. Altern Lab Anim 32:525-532
18 222 Scully LR, Bidochka MJ (2006) Developing insect models for the study of current and emerging human
19 223 pathogens. FEMS Microbiol Lett 263:1-9
20 224 Steinert M, Leippe M, Roeder T (2003) Surrogate hosts: protozoa and invertebrates as models for
21 225 studying pathogen-host interactions. Int J Med Microbiol 293:321-332
22 226 Tanowitz HB, Weiss LM, Wittner MD (2001) Tapeworms. Curr Infect Dis Rep 3:77-84
23 227 Thomas H, Gönner R (1977) The efficacy of Praziquantel against cestodes in Animals. Parasitol Res
24 228 52:117-127
25 229 Varma T, Shinghal T, Saxena M, Ahluwalia S (1989) Studies on the comparative efficacy of
26 230 mebendazole, flubendazole and niclosamide against human tapeworm infections. Indian J
27 231 Public Health 34:163-168
28 232

29 233 **Fig. 1.:** The effect of three anthelmintics at each of four concentrations and controls (0%) on the *in*
30 234 *vitro* activation of larval *Hymenolepis diminuta*. The data represent the mean percentage of activated
31 235 cysticercoids across three repeats. Error bars (S.E.M.).

32 236
33 237
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1

[Click here to download Figure: Figure 1.docx](#)

